IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)–mutant glio...

This week #JournalClub @labsoap.bsky.social @science.org #glioblastoma #IDH1 www.science.org/doi/10.1126/...

Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

TIBSOVO Expands Its Role in Targeted Cancer Therapy for IDH1 Mutations TIBSOVO, a targeted treatment for IDH1 mutations, is revolutionizing cancer therapy, addressing critical patient needs through its effectiveness in AML and cholangiocarcinoma.

TIBSOVO Expands Its Role in Targeted Cancer Therapy for IDH1 Mutations #United_States #Las_Vegas #Servier #Tibsovo #IDH1

Therapy enhancing chromosome instability may be advantageous for IDH1R132H/WT gliomas Abstract. Recently revised brain tumor classification suggested a glioma treatment strategy that takes into consideration molecular variants in IDH1 and TP

🔬Genetic mutations in gliomas (IDH1R132H/TP53R248Q) increase chromosomal instability; cells with these are more sensitive to paclitaxel and temozolomide, suggesting new targeted therapies. Read more in NAR Cancer: doi.org/10.1093/narc...
#CancerResearch #Glioma #IDH1 #TP53 #Paclitaxel #Temozolomide